Invivyd, Inc.
Waltham, MA · Founded 2020 · CIK 0001832038 · Biotech · Public
Antibody-based therapies designed to target evolving viral threats
invivyd.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $489M
- 4 Form D · Nov 2022
- 46 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 0 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $79,999,816 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $49,900,000 | |
| Private capital raised | Form D · SEC | $335,499,458 | |
| Private capital raised | Form D · SEC | $23,749,998 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2772 | LACERTA THERAPEUTICS, INC. | — | $500K |
| 2773 | StaphOff Biotech, Inc. | — | $25K |
| 2774 | Arsenal Biosciences | — | $579M |
| 2775 | Invivyd, Inc. | — | $489M |
| 2776 | Recursion Pharmaceuticals, LLC | — | $466M |
| 2777 | CARTESIAN THERAPEUTICS INC | — | $446M |
| 2778 | Genetic Networks, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jill AndersenExecutive Officer
- Tamsin BerryDirector
- Philip ChaseDirector
- Lynn ConnollyExecutive Officer
- Rebecca DaboraExecutive Officer
- Fred DriscollExecutive Officer
- Marc EliaDirector
- Tillman GerngrossDirector · Executive Officer
- Halley GilbertExecutive Officer
- Jane HendersonExecutive Officer
- David HeringDirector · Executive Officer
- Ellie HershbergerExecutive Officer
- Tom HeymanDirector
- Eric KimbleExecutive Officer
- Christine LindenboomDirector
- Howard MayerDirector
- Terrance McGuireDirector
- Terry McGuireDirector
- Clive MeanwellDirector
- Ajay RoyanDirector
- Rene RussoDirector
- Laura WalkerExecutive Officer
- Michael WyzgaDirector
Patents
- SARS-COV2 Antibodies And Methods Of Use Thereofapplication
- SARS-COV2 Antibodies And Uses Thereofapplication
- SARS-COV2 Antibodies And Uses Thereofapplication
- Pharmaceutical Formulations Comprising Anti-coronavirus S Protein Antibodies And Uses Thereofapplication
- SARS-COV2 Antibodies And Methods Of Uses Thereofapplication
- SARS-COV2 Antibodies And Methods Of Uses Thereofapplication
- SARS-COV2 Antibodies And Methods Of Uses Thereofapplication
- SARS-COV2 Antibodies And Methods Of Uses Thereofapplication
- SARS-COV2 Antibodies And Methods Of Uses Thereofapplication
- SARS-COV2 Antibodies And Uses Thereofapplication
- SARS-COV2 Antibodies And Uses Thereofapplication
- SARS-COV2 Antibodies And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.